These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22642325)

  • 1. Bispecific antibodies and diabodies for cancer immunotherapy.
    Elsässer-Beile U; Bühler P
    Immunotherapy; 2012 May; 4(5):459-60. PubMed ID: 22642325
    [No Abstract]   [Full Text] [Related]  

  • 2. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 3. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
    Riffard C; Teillaud JL
    Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibodies engage T cells for antitumor immunotherapy.
    Choi BD; Cai M; Bigner DD; Mehta AI; Kuan CT; Sampson JH
    Expert Opin Biol Ther; 2011 Jul; 11(7):843-53. PubMed ID: 21449821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of functional activities of human lymphocytes by monoclonal antibodies.
    Melioli G; Prigione I; Merlì A; Cantoni C; Chen Q; Machi AM; Ferrini S
    Ann Ist Super Sanita; 1991; 27(1):79-85. PubMed ID: 1835570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific T-cell engagers for cancer immunotherapy.
    Huehls AM; Coupet TA; Sentman CL
    Immunol Cell Biol; 2015 Mar; 93(3):290-6. PubMed ID: 25367186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
    Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
    Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ; Hillstrom JR
    J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel costimulators in the immune gene therapy of cancer.
    Galea-Lauri J; Farzaneh F; Gäken J
    Cancer Gene Ther; 1996; 3(3):202-14. PubMed ID: 8725885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.
    Zhukovsky EA; Morse RJ; Maus MV
    Curr Opin Immunol; 2016 Jun; 40():24-35. PubMed ID: 26963133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
    Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
    Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
    Kuo SR; Wong L; Liu JS
    Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
    Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH
    MAbs; 2014; 6(2):381-91. PubMed ID: 24492297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte subsets and surface molecules in man.
    Krensky AM; Lanier LL; Engleman EG
    Clin Immunol Rev; 1985; 4(1):95-138. PubMed ID: 2992859
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules.
    Ferrini S; Cambiaggi A; Cantoni C; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
    Int J Cancer Suppl; 1992; 7():15-8. PubMed ID: 1428398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.